Repetitively Dosed Docetaxel and (153)Samarium-EDTMP as an Anti-Tumor Strategy for Metastatic Castration-Resistant Prostate Cancer

BACKGROUND: Beta-emitting bone-seeking radiopharmaceuticals have historically been administered for pain palliation while docetaxel prolongs life in metastatic castration-resistant prostate cancer (mCRPC). In combination, these agents simultaneously target the bone stroma and cancer cell to optimize...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Autio, Karen A., Pandit-Taskar, Neeta, Carrasquillo, Jorge A., Stephenson, Ryan D., Slovin, Susan F., Rathkopf, Dana E., Hong, Christina, Heller, Glenn, Scher, Howard I., Larson, Steven M., Morris, Michael J.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3775970/
https://ncbi.nlm.nih.gov/pubmed/23765638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28103
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items